Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial; ...

“These results represent a significant milestone for PALI-2108,” said JD Finley, Chief Executive Officer of Palisade Bio. “The early clinical activity, targeted delivery, dose flexibility, the ...

Gain insights into EyePoint Pharmaceuticals' Q2 2025 performance, featuring DURAVYU's Phase III progress in wet-AMD, global expansion, and ...